For example, patients receiving dialysis care at over 6,000 dialysis facilities across the US typically dialyze three times per week and they are monitored regularly with respect to a variety of patient outcomes, including dialysis adequacy (sufficient removal of waste from blood); bone and mineral disorder (e.g., to prevent high calcium in the blood or hypercalcemia); phosphorous level; regulation of blood pressure; and hemoglobin (Hb) to manage anemia among other conditions. This evidence concerns the gene GSTM1 and anemia.